

Form PTO-1449

Sheet 1 of 6

Applicant: B. Ron Johnson

Serial No.: 10/816,571

Att'y Docket No.: 15070.6.2

Filing Date: April 1, 2004

Examiner: Donna A. Jagoe

Confirmation No.: 1232

For: ANTI-INFECTIVE COMPOSITIONS, METHODS AND SYSTEMS
FOR TREATING PATHOGEN-INDUCED DISORDERED TISSUESINFORMATION DISCLOSURE CITATIONS MADE BY APPLICANTForeign Patent Documents

<u>Examiner Initial*</u>	<u>Document Number</u>	<u>Publ. Date</u>	<u>Country or Patent Office</u>	<u>Class</u>	<u>Sub Class</u>	<u>Trans- lation</u>
___ 1	2,143,136	08/23/96	Canada	6		---
___ 2	2 700 698	07/29/94	France	3		Yes
___ 3	0 478 445	09/24/91	France	3	48	
___ 4	0 190 797	08/13/86	EPO	4		---
___ 5	0 181 184	05/14/86	EPO	4		---
___ 6	1 479 480	07/13/77	GB	2		
___ 7	WO 99/08713	02/25/99	PCT	6		---
___ 8	WO 98/11778	03/26/98	PCT	A01N	33/12	Yes
___ 9	WO 98/42188	10/01/98	PCT	A01N	33/12	Yes

Other Documents

(including author (if listed), title, relevant pages, date of publication including at least month and year).

Examiner
Initial*

Examiner:

Date Considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant: B. Ron Johnson

Serial No.: 10/816,571

Att'y Docket No.: 15070.6.2

Filing Date: April 1, 2004

Examiner: Donna A. Jagoe

Confirmation No.: 1232

For: ANTI-INFECTIVE COMPOSITIONS, METHODS AND SYSTEMS
FOR TREATING PATHOGEN-INDUCED DISORDERED TISSUES

-
- ____ 10 *AHFS Drug Information*, pages 3107-3108, 1999.
- ____ 11 Physicians Desk Reference for Non-Prescription Drugs, Product Information, pgs. 643, 644, 649, 503, 507, and reference pages to Bactine, and Tanac, 1998.
- ____ 12 Winthrop Laboratories, ZEPHIRAN® CHLORIDE, Informational Brochure, July, 1980.
- ____ 13 Encyclopedia Britannica, Inc., Definitions of SKIN and SKIN, DISEASES OF, pgs. 603-609, 1970
- ____ 14 *DentalDots® What are they?*, located at "http://www.dentaldots.com/whatsadot.htm," page 1, web page dated July 14, 1999.
- ____ 15 *Viramedx/Really Fast Relief for Herpes Related Outbreaks*, located at "http://www.viramedx.com/", 1 page, web page dated 6/28/99.
- ____ 16 *Cold Sores Healed in Less than 24 Hours Report Says*, located at "http://www.viramedx.com/news01.htm," 2 pages, web page dated 6/28/99.
- ____ 17 *Comparison of Zovirax, Valtrex, Famvir and VirMedx*, located at "http://www.viramedx.com/compare..htm," 1 page, web page dated 6/28/99.
- ____ 18 *Herpes Treatment That Works on Genital Herpes Too*, located at "http://www.viramedx.com/about.htm," 1 page, web page dated 6/28/99.
- ____ 19 *Herpes Treatment Shows Promise Against Genital Herpes*, located at "http://viramedx.com/study.htm," 1 page, web page dated 6/28/99.
- ____ 20 *Results Against Clinical Strains of Herpes Simplex Virus*, located at "http://www.ciramedx.com/labdata.htm," 1 page, web page dated 6/28/99.
-

Examiner:

Date Considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant: B. Ron Johnson

Serial No.: 10/816,571

Att'y Docket No.: 15070.6.2

Filing Date: April 1, 2004

Examiner: Donna A. Jagoe

Confirmation No.: 1232

For: ANTI-INFECTIVE COMPOSITIONS, METHODS AND SYSTEMS
FOR TREATING PATHOGEN-INDUCED DISORDERED TISSUES

-
- _____ 21 *8 Year Study to Determine Effectiveness Against Herpes*, located at "<http://viramedx.com/clinicaldata.htm>," 1 page, web page dated 6/28/99.
- _____ 22 *8 Year Study to Determine Effectiveness Against Herpes*, located at "<http://www.ciramedx.com/results.htm>," 5 pages, web page dated 6/28/99.
- _____ 23 *8 Year Study to Determine Effectiveness Against Herpes*, located at "<http://www.viramedx.com/clinicalsum.htm>," 2 pages, web page dated 6/28/99.
- ~~_____ 24 *Sigma Product Information Sheet, Benzalkonium Chloride*, located at "<http://www.sigma.sial.com/sigma/proddata/b1383.htm>.~~
- _____ 25 *ViraMedix, Antiviral Activity of Viracea® Against Acyclovir Resistant Strains of Herpes Simplex Virus (HSV)*, located at "<http://www.herpescontrol.com/acyresist.htm>," by K.D. Thompson et al., The University of Chicago and Meryx Pharmaceutical, Chicago, IL (study results found at <http://www.herpescontrol.com/figure3.htm>), © 1998.
- _____ 26 *ViraMedix News Release, Announcing the First OTC Treatment Proven to "Kill" the Herpes Virus that Causes Cold Sores, Fever Blisters and Related Outbreaks, Healing the Outbreak in Usually Less Than 24 Hours/Timely Introduction in Light of Recent News of the Spread of Herpes Caused Outbreaks and Just in Time for the Summer Sun Caused Outbreaks of Cold Sores*, located at <http://www.herpescontrol.com/news01.htm>, © 1998.
- _____ 27 *Study Results, Testimonials*, located at <http://www.herpescontrol.com/results.htm>, © 1998.
- _____ 28 Berti, et al., *Transcutaneous Drug Delivery: A Practical Review*, Mayo Clin. Proc., Vol. 70, pages 581-586, June 1995.
-

Examiner:

Date Considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant: B. Ron Johnson

Serial No.: 10/816,571

Att'y Docket No.: 15070.6.2

Filing Date: April 1, 2004

Examiner: Donna A. Jagoe

Confirmation No.: 1232

For: ANTI-INFECTIVE COMPOSITIONS, METHODS AND SYSTEMS
FOR TREATING PATHOGEN-INDUCED DISORDERED TISSUES

-
- ____ 29 Choi, et al., *The Pretreatment Effect of Chemical Skin Penetration Enhancers in Transdermal Drug Delivery Using Iontophoresis*, Skin Pharmacol. Appl. Skin Physiol., pages 326-335, 1999.
- ____ 30 Comfort et al., *Enhanced Transport in a Therapeutic Transdermal System*, Biomaterials, Vol. 11, No. 9, pages 729-733, November 1990.
- ____ 31 Fang et al., *Development and Evaluation on Transdermal Delivery of Enoxacin Via Chemical Enhancers and Physical Iontophoresis*, Journal of Controlled Release, Vol. 54, pages 293-304, 1998.
- ____ 32 Fang et al., *Evaluation of Transdermal Iontophoresis of Enoxacin From Polymer Formulations: In Vitro Skin Permeation and In Vivo Microdialysis Using Wistar Rat as an Animal Model*, International Journal of Pharmaceutics 180, pages 137-149, 1999.
- ____ 33 Gismondo, et al., *Efficacia Antimicrobica e Sporidica di Varie Soluzioni Disinfettanti*, Minerva Medica, (Italy) Vol. 86, pages 21-32, January-February 1995 (English translation attached: *Antimicrobial and Sporicidal Efficacy of Some Disinfectant Solutions*).
- ____ 34 James Alexander Corporation flyer, *Medicaine® Sting and Bite Relief Formula Flyer*, 1997.
- ____ 35 James Alexander Corporation flyer, *Medicaine® Topical Antiseptic*, 1997.
- ____ 36 James Alexander Corporation flyer, *Unit Dose Swabs*, 1997.
- ____ 37 Jin et al., *Effect of Application Volume of Ethanol-Isopropyl Myristate Mixed Solvent System on Permeation of Zidovudine and Probenecid Through Rat Skin*, Drug Development and Industrial Pharmacy, Vol. 26 No. 2, pages 193-198, 2000.
-

Examiner:

Date Considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant: B. Ron Johnson

Serial No.: 10/816,571

Att'y Docket No.: 15070.6.2

Filing Date: April 1, 2004

Examiner: Donna A. Jagoe

Confirmation No.: 1232

For: ANTI-INFECTIVE COMPOSITIONS, METHODS AND SYSTEMS
FOR TREATING PATHOGEN-INDUCED DISORDERED TISSUES

-
- ____ 38 Johnson, et al., *Supergistic Effects of Chemical Enhancers and Therapeutic Ultrasound on Transdermal Drug Delivery*, Journal of Pharmaceutical Sciences, Vol. 85, No. 7, pages 670-679, July 1996.
- ____ 39 Kanikkannan, et al., *Structure-Activity Relationship of Chemical Penetration Enhancers in Transdermal Drug Delivery*, *Current Medicinal Chemistry*, Vol. 7, No. 6, pages 593-608, 2000.
- ____ 40 Martindale, The Extra Pharmacopoeia, *Benzethonium Chloride/Benzyl Alcohol*, page 1119, Royal Pharmaceutical Society, 1996.
- ____ 41 Martindale, The Extra Pharmacopoeia, *Disinfectants and Preservatives*, pages 1114-1116, Royal Pharmaceutical Society, 1996.
- ____ 42 Martindale, The Extra Pharmacopoeia, *Ethyl Hydroxybenzoate/Magenta*, page 1137, Royal Pharmaceutical Society, 1996.
- ____ 43 Martindale, The Extra Pharmacopoeia, *Local Anesthetics*, pages 1317, 1320-1321, Royal Pharmaceutical Society, 1996.
- ____ 44 The Merck Index, An Encyclopedia of Chemicals, drugs, and Biologicals, Twelfth Edition, pages 177 and 180, 1996.
- ____ 45 Meyler's Side Effects of Drugs, An Encyclopedia of Adverse Reactions and Interactions, *Antiseptic Drugs and Disinfectants*, Chapter 24, pages 643-644 and 664-665, 1996.
- ____ 46 Sanofi Pharmaceuticals, Inc., *Zephiran® Chloride*, Brand of Benzalkonium Chloride, 1997.
- ____ 47 Williams, et al., *Skin Absorption Enhancers*, Critical Reviews in Therapeutic Drug Carrier Systems, 9(3,4), pages 305-353, 1992.
-

Examiner:

Date Considered:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant: B. Ron Johnson

Serial No.: 10/816,571

Att'y Docket No.: 15070.6.2

Filing Date: April 1, 2004

Examiner: Donna A. Jagoe

Confirmation No.: 1232

For: ANTI-INFECTIVE COMPOSITIONS, METHODS AND SYSTEMS
FOR TREATING PATHOGEN-INDUCED DISORDERED TISSUES

-
- _____ 48 Wu et al., *In Vitro Effect of Penetration Enhancers on Sodium Nonivamide Acetate in Rat Skin*, Biol. Pharm. Bull., Vol. 18, No. 12, pages 1790-1792, 1995.

References Cited by Applicants

While the filing of Information Disclosure Statements is voluntary, the procedure is governed by the guidelines of Section 609 of the Manual of Patent Examining Procedure and 37 C.F.R. §§ 1.97 and 1.98. To be considered a proper Information Disclosure Statement, Form PTO-1449 shall be accompanied by a copy of each listed patent or publication or other item of information and a translation of the pertinent portions of foreign documents (if an existing translation is readily available to the applicant), an explanation of relevance of each reference not in the English language, and should be submitted in a timely manner as set out in MPEP Sec. 609.

Examiners will consider all citations submitted in conformance with 37 C.F.R. § 1.98 and MPEP Sec. 609 and place their initials adjacent the citations in the spaces provided on this form. Examiners will also initial citations not in conformance with the guidelines which may have been considered. A reference may be considered by the Examiner for any reason whether or not the citation is in full conformance with the guidelines. A line will be drawn through a citation if it is not in conformance with the guidelines AND has not been considered. A copy of the submitted form, as reviewed by the Examiner, will be returned to the applicant with the next communication. The original of the form will be entered into the application file.

Each citation initialed by the Examiner will be printed on the issued patent in the same manner as references cited by the Examiner on Form PTO-892.

The reference designations "A1," "A2," etc. (referring to Applicant's reference 1, Applicant's reference 2, etc.) will be used by the Examiner in the same manner as Examiner's reference designations "A," "B," "C," etc. on Office Action Form PTO-1142.

W:15070.6.2JMG0000001186V001.doc

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.J./

Examiner:

Date Considered:

05/13/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.